Overall survival
OS rates were 97.0% in the eltrombopag group and 96.0% in the control
group at the last follow-up. Two patients (3.0%) died in the
eltrombopag group, including one who died at 12 months after diagnosis
of SAA without hematologic response; the other patient died of
hematopoietic stem cell transplantation (HSCT) complications. Two
patients (4.1%) died in the control group, including one who died after
2 years without hematologic response; the other case died of
transplantation complications. Totally 10 patients (20.4%) were lost at
the end of follow-up in the control group (Table 2). There was no
significant difference in OS between the two groups (P=0.999) (Figure
1).